Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +0.70% 36.00p 35.00p 37.00p 36.50p 35.75p 35.75p 88,465 14:05:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 26.93

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
20/9/201713:02ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET7,778
16/3/201720:00ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."3,646
08/10/201612:43Angle PLC 201130,115
02/12/201513:04Angle 2016 – Liquid Biopsy Takeover Target-
11/6/201508:16MrKeysersoze39

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:56:5836.964,0581,499.84O
14:29:5336.752,693989.68O
13:05:0835.755,0001,787.50O
10:51:2436.4528,25710,299.68OK
10:48:3136.4828,78210,499.67OK
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

DateSubject
20/9/2017
09:20
Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 35.75p.
Angle Plc has a 4 week average price of 32.25p and a 12 week average price of 32.25p.
The 1 year high share price is 80p while the 1 year low share price is currently 32.25p.
There are currently 74,815,774 shares in issue and the average daily traded volume is 139,134 shares. The market capitalisation of Angle Plc is £26,933,678.64.
14/9/2017
18:20
miavoce: Hi Fray, hope you are well. I've scanned through my posts since start of the year and I can't seen any posts which appear to be ramping. There are lots of posts bringing peoples attention to where Parsortix is being referenced at conferences and attention to publications featuring Parsortix, posts with analysis of results, comments on mgt performance, and posts challenging incorrect information (such as Bones's statements about aim shares) etc. but nothing forecasting a share price increase or suchlike. I accept that on balance my posts are more broadly positive than critical (although there are several of these) and I do try to maintain a positive tone, but they don't appear to be 'ramping'. I do however firmly believe that AGL will be a great success and that my investment will pay off in the long term - and like everybody else I find the pace of progress very frustrating (and I fully accept that I have previously been over optimistic on the timeframes). Good call on the fall in the share price by the way - you called it a long time ago and have been proven correct - I hope you profited from it.
13/9/2017
09:00
sicilian_kan: No miavoce I'm not suggesting that. That would be crazy to think. But companies have a degree of control over the release of news. E.g. when to sign the contract etc. They also have much greater control over when to time a placing and can time it around newsflow. So the two can go hand in hand and often do. Newland's problem is that he has left it far, far too late. I expect he initially would have preferred to place after the ovarian results, expecting the share price to rise, and then it didn't. Instead, the share price more than halved from its high. It kept on falling and was volatile. I doubt very much that this would have happened if Angle was well funded, which it is not. The market has driven the price down expecting funding needs and given the vagaries of the ovarian RNS with its claims of "up to 95%", which without more information as to what "up to" means is fairly useless. In summary, any fundraising in the 30p region will be a total failure. It will be raising funds at a near 5 year low, despite all the scientific progress. If you want any indictment on Newland, if he does place in the 30p region, that will be all the evidence you need to show his failings as a CEO. What Newland does is to head down incorrect paths (FDA approval), announcing unrealistic timetables (e.g. the repeated delays to ovarian), whilst looking after number one (i.e. himself) over and above the best interests of the company shareholders (his share sales and buybacks, accepting his far too high bonuses etc). For me, Newland has lost credibility. I just cannot rely upon his statements about timings etc. There are only so many times the pudding can (looking retrospectively) be overegged, however inadvertently. Of course, I accept that Angle has made massive progress scientifically and the company is a lot further ahead, but the share price is categorically in a bad, bad place. Many shareholders will be in a position of a loss and the potential dilution here will be significant. Yes, a deal or some other funding arrangement might come along that will be much better than a placing at these levels and could obviate the need for significant dilution. But given where the share price is, the market does not believe that this will be the case. The market may be wrong of course, but usually it is correct at times such as this one.
12/9/2017
14:47
bones698: Don't think we will agree on that as the chart says otherwise . I haven't seen any news that suggests contrary or that other things are in place or even being considered . The accountants will also want to see agl has adequate funding going forward to sign off accounts . Happy to wait and see but you can't ignore the share price reaction which has happened for a reason . I posted some time ago I felt AN had missed the boat not accelerating sales in other countries were they had approval , yesterdays rns made me chuckle a bit . At least it's progress albeit later thanit should have been imo and again the impact remains to be seen and will take time to filter through into results. Be fair I also said the longer they left it the worse it would be on the share price and here we are lol The grants etc as you say may help a little but aren't large sums of money in reality . So going off the last known figure and estimated cash burn how long do you think they have before they run out ? I reckon April is pushing it imo. Wether they can find a deal or have to raise funds we will see but the latter is certainly risky and painful the longer it's left . For your sake I hope they can find a deal or something and I do appreciate there are other possibilities but they are cutting it fine imo
07/9/2017
22:50
fraybentos2: fao stevelauren23 i have posted 18 times of the agl board in 2017, until now you have posted 80 times yet you accuse me of trying to influence the share price one post every two weeks from me...on average...but the gaps are usually far more as I tend to post a couple or more at a time, so perhaps once every six weeks ... trying to influence the share price you are crazy
07/9/2017
22:37
bones698: Steve et al , I have been posting on this board for more than 6 years although less frequently in the past . As things have deteriorated and reading the utter garbage some of the bulls post I have posted more frequently . The fact they are trying to call my motives and statements into question with absolutely zero facts to back up their claims is comical. I can see very few have bothered to look back at my posts which have predicted the demise of agls fortunes . Try all you like but the simple fact is the management have messed up, they are running out of cash fast and need.to raise funds and the share price is taking because they have been far to slow to react to the situation . The market see doubts and lack.of funds and have trashed the share price knowing what is to come. Sad to see So many stale bulls completely blinded by their hopes rather than seeing the situation forwhat it is. Its not my fault your losing money and it's quite amusing to see the usual attacks on anyone posting negative comments just because you messed up thinking agl would be successful . Steve I suggest you read escapes posts again , he is calling the bulls not the bears like me idiot . Call my pigeon English all.you like but appears many bulls can't even read lmao
07/9/2017
16:48
willfy: It takes time to get a new broker in place, so possibly after the Ovarian results were out, and the share price started its long drift, the board acted swiftly in appointing fincap.Honestly do not believe the share price will be at this level by end of October, can you imagine attending the AGM if the share price were at 25 p ?Fully expecting a partial re-rating of some sought, and hopefully substantial news as well.
11/6/2017
15:55
alloa2003: Personally I think if AGL had taken this slowly slowly approach a couple of years ago the share price would be much higher. We have suffered from mismanagement of expectations but hopefully the BOD have learnt a lesson. Let the results come through and let them speak for themselves. Trying to guess when the FDA might act on AGL's application(s) is a waste of time but good trial results will put more pressure on the FDA. Share price targets of £5 are unrealistic at this moment in time but we could have a game changing year and a rejuvenated share price. First of all we need to see constant positive news flow and better management of expectations. The recent research note suggesting a share price of 187p (from memory) seems ambitious but achievable in this very volatile area in which AGL operates. One of the other keys is to maximise the current benefits of Parsortix over competing system asap - that way we get a foothold in the market. Once we are there, the companies who operate in this area will not be changing their systems every 2 minutes and only then will we see the sales flow that everyone has been hoping for.
20/12/2016
18:51
adorling: At least those greedy Directors will need to get the share price to 129p before they can exercise those options granted in November! "The exercise price for the new share options is 64.50 pence per share, representing the Company's closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions. The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued."
10/12/2016
18:23
m5: Elbillo8 Dec '16 - 20:33 - 4518 of 4553 No disrespect, ignoring a share price because you have faith in the Company can be a dangerous game IMHO. Are you saying that if the share price dropped to 30p you would be still comfortable? It is rare that the market gets it consistently wrong. At the end of the day the only thing that does matter is the share price I do not see anything with the share price at the moment that causes concern as the share price is trading within its range, however should it move outside of that range I would be paying attention, that applies to both the upper and lower levels. I would say flexibility in any share is the key, if you sell you can always buy back. I wish all holders the best of luck.
28/11/2016
07:17
gary38: Angle PLC ISSUE OF SHARE OPTIONSSource: UK Regulatory (RNS & others)TIDMAGLRNS Number : 2366QAngle PLC28 November 2016 For immediate release 28 November 2016 ANGLE plc("ANGLE" or the "Company")ISSUE OF SHARE OPTIONSANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, announces that under the shareholder approved Remuneration Policy the Remuneration Committee has approved the issue of 1,500,000 share options to the Company's executive directors. The Remuneration Committee has also approved the issue of 1,805,000 share options to certain staff.Following the issue of these share options, the Company will have outstanding options over a total of 10,365,806 ordinary shares of GBP0.10, representing approximately 11.6% of its issued and to be issued share capital. This leaves approximately 3.9 million options unallocated within the approved limit of up to 16% of the issued and to be issued share capital from time to time.The exercise price for the new share options is 64.50 pence per share, representing the Company's closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions.The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued.Following the issue of the new share options, the total number of share options held by the executive directors of the Company will be:
Angle share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170920 20:10:55